AbCellera Biologics Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Trading alerts issued for AbCellera Biologics (ABCL) on NASDAQ. A covered call strategy is recommended for half of the long position. The price target is set at $20. ABCL's stock has recently spiked due to positive phase 2 data for ABCL635.
AbCellera Biologics (ABCL) shares rose 9% on Friday and 4% after hours, marking an 18% weekly gain. Investors anticipate Q1 2026 earnings and clinical data for ABCL635, a non-hormonal menopause treatment. Baker Bros. increased its stake to 10.8%. Analysts expect $5.84M revenue and a $0.19 loss per share. The average price target is $9.14, with 8 of 9 analysts rating it 'Buy' or higher.
AbCellera (ABCL) reported Q2 2026 revenue of $4.1M, down from $17.1M YoY, with a net loss of $55.4M. The company advanced its pipeline, including ABCL635, which met primary endpoints in a Phase 2 study, and announced collaborations with Jazz and Vertex Pharmaceuticals, receiving upfront payments totaling $112M. ABCL ended the quarter with $675M in liquidity. Shares are up 16.78% to $12.40.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ABCL (AbCellera Biologics Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ABCL coverage spans insider activity, technology and earnings.
In the last 30 days, ABCL insiders filed 4 SEC Form 4 transactions — 4 purchases ($1.5M) and no sales. The most active reporter was Hayden Michael R with 2 filings.
Positive Phase 2 results could drive near‑term buying pressure and set up longer‑term upside if data are confirmed.
Earnings and clinical data could drive a sharp price move.
Earnings miss revenue expectations but cash runway improves; Phase 2 trial shows statistically significant efficacy, likely boosting near‑term sentiment.
Trial data suggests strong efficacy, likely fueling further upside as the drug advances.
The purchase signals confidence from a board member, potentially supporting the stock.
alphai scores every news story that mentions ABCL with an AI model for sentiment and relevance, and aggregates insider trades from AbCellera Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Trading alerts issued for AbCellera Biologics (ABCL) on NASDAQ. A covered call strategy is recommended for half of the long position. The price target is set at $20. ABCL's stock has recently spiked due to positive phase 2 data for ABCL635.
1 min readAbCellera Biologics (ABCL) shares rose 9% on Friday and 4% after hours, marking an 18% weekly gain. Investors anticipate Q1 2026 earnings and clinical data for ABCL635, a non-hormonal menopause treatment. Baker Bros. increased its stake to 10.8%. Analysts expect $5.84M revenue and a $0.19 loss per share. The average price target is $9.14, with 8 of 9 analysts rating it 'Buy' or higher.
2 min readAbCellera (ABCL) reported Q2 2026 revenue of $4.1M, down from $17.1M YoY, with a net loss of $55.4M. The company advanced its pipeline, including ABCL635, which met primary endpoints in a Phase 2 study, and announced collaborations with Jazz and Vertex Pharmaceuticals, receiving upfront payments totaling $112M. ABCL ended the quarter with $675M in liquidity. Shares are up 16.78% to $12.40.
3 min readAbCellera Biologics' stock rose 14.85% to $12.19, a 52-week high, driven by positive Phase 2 trial results for its menopause drug ABCL635 and bullish analyst price target increases. The company's market value reached $3.4 billion, with analysts raising targets to $25. Despite strong gains, the stock is considered overvalued by some metrics. AbCellera also secured collaborations with Vertex and Jazz Pharmaceuticals, bringing in $100 million in upfront payments. The company reported growing revenu
2 min readHayden Michael R purchased 53,613 indirectly-held shares of AbCellera Biologics Inc. (ABCL) at $10.64 ($0.57M total) on 2026-08-24.
1 min readMontalbano John S. purchased 10,000 shares of AbCellera Biologics Inc. (ABCL) at $11.03 ($0.11M total) on 2026-08-18.
2 min readAbCellera Biologics (NASDAQ:ABCL) shares rose about 64% week over week after phase 2 results for ABCL635, a treatment for hot flashes in menopausal women. In 92 postmenopausal patients, hot flash episodes fell 83% versus 33% with placebo. Truist raised its price target to $30 and peak risk-adjusted sales to $1.1B.
4 min readAbCellera (ABCL) and Vertex (VRTX) announced a strategic collaboration to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery using its TCE platform and receive $28M upfront plus milestones and tiered royalties, while Vertex funds R&D and retains commercialization rights. The article also cites Vertex Q2 2026 revenue of $3.33B and net income of $1.1B, and AbCellera Q2 2026 revenue of $4.1M with a $55.4M net loss.
7 min readAbCellera (ABCL) hit a 52-week high after Phase 2 results for ABCL635 showed an 83% reduction in symptom frequency versus 33% for placebo, and Jones Research raised its price target to $25. Replimune (REPL) reached a 52-week high on a $150M financing. Airbnb (ABNB) rose to a four-year high on Q2 results and a $4.69B-$4.77B Q3 outlook.
6 min readBooth Andrew (Chief Financial Officer) purchased 37,200 shares of AbCellera Biologics Inc. (ABCL) at $10.32 ($0.38M total) on 2026-08-14.
1 min read
